CA3265264A1 - Anticorps anti-ccr8 et leurs utilisations - Google Patents
Anticorps anti-ccr8 et leurs utilisationsInfo
- Publication number
- CA3265264A1 CA3265264A1 CA3265264A CA3265264A CA3265264A1 CA 3265264 A1 CA3265264 A1 CA 3265264A1 CA 3265264 A CA3265264 A CA 3265264A CA 3265264 A CA3265264 A CA 3265264A CA 3265264 A1 CA3265264 A1 CA 3265264A1
- Authority
- CA
- Canada
- Prior art keywords
- ccr8 antibodies
- ccr8
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263399483P | 2022-08-19 | 2022-08-19 | |
| US63/399,483 | 2022-08-19 | ||
| PCT/US2023/072462 WO2024040216A2 (fr) | 2022-08-19 | 2023-08-18 | Anticorps anti-ccr8 et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3265264A1 true CA3265264A1 (fr) | 2024-02-22 |
Family
ID=88020873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3265264A Pending CA3265264A1 (fr) | 2022-08-19 | 2023-08-18 | Anticorps anti-ccr8 et leurs utilisations |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4573126A2 (fr) |
| JP (1) | JP2025527535A (fr) |
| KR (1) | KR20250052418A (fr) |
| CN (1) | CN120051493A (fr) |
| AU (1) | AU2023325323A1 (fr) |
| CA (1) | CA3265264A1 (fr) |
| WO (1) | WO2024040216A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024248037A1 (fr) | 2023-05-30 | 2024-12-05 | 塩野義製薬株式会社 | Anticorps bispécifique qui reconnaît ccr8 en tant qu'antigène |
| WO2025145207A1 (fr) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Polythérapie d'inhibiteur de kras et d'agent de déplétion des treg |
| CN121779523A (zh) * | 2026-03-05 | 2026-04-03 | 山东中医药大学 | 一种鳗草来源的多肽及其提升岩藻糖含量的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1993016185A2 (fr) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Proteine de liaison biosynthetique pour marqueur de cancer |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| ES2393555T3 (es) | 2003-10-22 | 2012-12-26 | Keck Graduate Institute | Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide. |
| WO2006076288A2 (fr) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Constructions d'adn pour l'expression a long terme d'adn nu en injection intravasculaire |
| TWI906906B (zh) * | 2020-01-06 | 2025-12-01 | 美商法西尼克斯股份有限公司 | 抗ccr8抗體及其用途 |
| CN117964757A (zh) * | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| CN115768792A (zh) * | 2020-03-23 | 2023-03-07 | 百时美施贵宝公司 | 抗ccr8抗体用于治疗癌症 |
| EP4267617A1 (fr) * | 2020-12-24 | 2023-11-01 | Vib Vzw | Liants ccr8 humains |
| US20250019451A1 (en) | 2021-08-20 | 2025-01-16 | Hifibio, Inc. | Anti-ccr8 antibodies and uses thereof |
-
2023
- 2023-08-18 EP EP23769061.5A patent/EP4573126A2/fr active Pending
- 2023-08-18 AU AU2023325323A patent/AU2023325323A1/en active Pending
- 2023-08-18 WO PCT/US2023/072462 patent/WO2024040216A2/fr not_active Ceased
- 2023-08-18 JP JP2025508900A patent/JP2025527535A/ja active Pending
- 2023-08-18 CN CN202380073161.0A patent/CN120051493A/zh active Pending
- 2023-08-18 CA CA3265264A patent/CA3265264A1/fr active Pending
- 2023-08-18 KR KR1020257008806A patent/KR20250052418A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4573126A2 (fr) | 2025-06-25 |
| KR20250052418A (ko) | 2025-04-18 |
| AU2023325323A1 (en) | 2025-03-27 |
| JP2025527535A (ja) | 2025-08-22 |
| CN120051493A (zh) | 2025-05-27 |
| WO2024040216A3 (fr) | 2024-04-11 |
| WO2024040216A2 (fr) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3254156A1 (fr) | Anticorps anti-cd84 et leurs utilisations | |
| CA3266237A1 (fr) | Anticorps anti-sars-cov2 et leurs utilisations | |
| CA3260932A1 (fr) | Anticorps spécifiques de cd25 et leurs utilisations | |
| CA3310135A1 (fr) | Anticorps ciblant cd40 et leurs utilisations | |
| CA3306831A1 (fr) | ANTICORPS ANTI-α-SYNUCLÉINE ET LEURS UTILISATIONS | |
| CA3307613A1 (fr) | Anticorps anti-ny-eso-1 et leurs utilisations | |
| CA3307647A1 (fr) | Anticorps anti-il-4 ra et leurs utilisations | |
| CA3304852A1 (fr) | Anticorps anti-tigit et leurs utilisations | |
| CA3305834A1 (fr) | Anticorps anti-cdh17 et leurs utilisations | |
| CA3304830A1 (fr) | Anticorps anti-tdp-43 et leurs utilisations | |
| CA3303332A1 (fr) | Anticorps anti-ly6 et leurs utilisations | |
| CA3299540A1 (fr) | Anticorps anti-b7-h3 et leurs utilisations | |
| CA3299545A1 (fr) | Anticorps anti-acvr2b et leurs utilisations | |
| CA3296337A1 (fr) | Anticorps anti-klrg1 et leurs utilisations | |
| AU2024312447A1 (en) | Anti-klrg1 antibodies and uses thereof | |
| CA3296478A1 (fr) | Anticorps et leurs utilisations | |
| CA3294517A1 (fr) | Anticorps anti-tigit et leurs utilisations | |
| CA3294500A1 (fr) | Anticorps anti-pvrig et leurs utilisations | |
| CA3291454A1 (fr) | Anticorps et leurs utilisations | |
| CA3292497A1 (fr) | Anticorps et leurs utilisations | |
| CA3291547A1 (fr) | Anticorps ciblant bdca2 et leurs utilisations | |
| CA3284726A1 (fr) | Anticorps anti-tmprss6 et leurs utilisations | |
| CA3291293A1 (fr) | Anticorps anti-cd16a et leurs utilisations | |
| CA3284328A1 (fr) | Anticorps et leurs utilisations | |
| CA3284518A1 (fr) | Anticorps ciblant ilt7 et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20250218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250520 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250520 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250521 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250521 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250521 |